Jun 8, 2024 · This educational activity focuses on epoetin alfa, an erythropoiesis-stimulating agent vital for managing anemia. Participants will learn about the indications for using epoetin alfa, which includes treating anemia associated with chronic kidney disease, myelosuppressive chemotherapy, and various other causes.

Epoetin alfa serves to restore erythropoietin deficiency in pathological and other clinical conditions where normal production of erythropoietin is impaired or compromised.

Reduced hemoglobin levels also stimulate EPO production, albeit indirectly. Erythropoiesis stimulating agents (ESA) are recombinant forms of EPO produced synthetically via recombinant DNA technology in cell cultures. ESAs include epoetin alfa, darbepoetin, and methoxy polyethylene glycol-epoetin β. [1]

Feb 17, 2020 · Includes Epoetin Alfa indications, dosage/administration, pharmacology, mechanism/onset/duration of action, half-life, dosage forms, interactions, warnings, adverse reactions, off-label uses and more.

Darbepoetin alfa is a hyperglycosylated EPO analog with an extended terminal half-life and a greater relative potency compared with rhEPO at extended dosing intervals. PEGylation of EPO (addition of polyethylene glycol) has been used to further extend the terminal half-life.

Jun 8, 2024 · Participants will learn about the indications for using epoetin alfa, which includes treating anemia associated with chronic kidney disease, myelosuppressive chemotherapy, and various other causes.

Dec 1, 2003 · The mechanism of action of endogenous erythropoietin and the therapeutic use of epoetin alfa to stimulate red blood cell production and improve the quality of life in cancer patients are reviewed here. Epoetin alfa may also attenuate …

Epoetin alfa, sold under the brand name Epogen among others, is a human erythropoietin produced in cell culture using recombinant DNA technology. [8][9] Epoetin alfa is an erythropoiesis-stimulating agent. [8]

Dec 1, 2008 · Erythropoietin (EPO) interacts directly with the EPO receptor on the red blood cell (RBC) surface, triggering activation of several signal transduction pathways, resulting in the proliferation and terminal differentiation of erythroid precursor cells and providing protection from RBC precursor apoptosis.

Aug 1, 2003 · The current article describes the basis and mechanism for the use of recombinant human erythropoietin (rHuEPO, epoetin alfa), a molecular targeted therapy, for the treatment of cancer-related anemia, with a focus on lung cancer.